With respect I think you worry too much here. Contrarian points and devil's advocates are welcome when many popular posts are preaching to the choir. However I sense a narrowness of focus in your persistent 'doubts' about short-term funding viability of Phylogica.
I know with micro-caps 'The Devil is in the Detail' as they say.
However a rational perspective would provide confidence that their funding requirement for the next 12 months are covered.
The more important concern, isn't for the company's viability in the short-term. That I believe, is a given across a broad consensus of experienced PYC and biotech watchers generally.
So my focus isn't whether they will receive the expected upfront fees on deals already signed, but HOW MANY MORE deals they will sign this year.
This is the share price sensitive news flow that I am both positive and quietly excited about. (Well maybe not so quiet) :)
Long term this stock, with it's baby market capitalisation, is more than 50% likely to be a 10-bagger. IMHO DYOR. I base this on an overview of the market capitalisation of what I (and other Biotech watchers) regard as comparable research and patent holding companies.
There is (apart from one competitor with parallel peptide library that I know of) a quite unique opportunity here with Phylogica because, like other juniors in the past (Cochlear comes to mind), they own patented ground-breaking, game-changing 'technology' in the bio-medical field.
No, I am not seriously comparing Phylogica to Cochlear! I just appreciate the company holds patents on a history making 'way forward' for anti-biotic and viral treatments delivery. These could reduce non-target cell and organ toxicity and lower doses across a range of KNOWN medicines, not new ones.
That is a wide field of opportunity for reducing human suffering, making medicine more cheaply available in the third world (eventually) and creating a stream of royalties for those who back this company.
In closing, Andrew I would like to humbly suggest you let your fingers do the walking and do some serious research of your own to 'get across' Phylogica in the broader sense, and post something here of interest to punters that is the fruit of your own labours.
That way you can truly put your mouth where your money is, so to speak and actualise your stated backing of this company.
With respect,
PatrickM
PYC Price at posting:
7.1¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)